Live attenuated influenza vaccine--a review

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Influenza virus variability necessitates annual vaccine updates.
• Current influenza vaccines are often sub-optimal due to various influencing factors.
• Live attenuated influenza vaccines (LAIVs) are a focus of recent research and development.

Purpose of the Study:

• To evaluate the efficacy and safety of a newly licensed cold-adapted attenuated influenza vaccine.
• To compare the effectiveness of LAIVs with inactivated influenza vaccines.
• To assess the potential of LAIVs for widespread use, particularly in pediatric populations.

Main Methods:

• Investigated a specific cold-adapted attenuated influenza vaccine strain developed by Maassab.
• Assessed vaccine safety, tolerability, and genetic stability.
• Evaluated vaccine effectiveness through comparative studies with inactivated influenza vaccines.

Main Results:

• The Maassab-developed LAIV is safe, well-tolerated, and genetically stable.
• LAIVs demonstrated effectiveness, sometimes exceeding that of inactivated influenza vaccines.
• While vaccine recipients can shed the virus, transmission to close contacts is minimal.

Conclusions:

• Cold-adapted attenuated influenza vaccines represent a significant advancement in influenza prevention.
• LAIVs offer a potentially more effective and acceptable alternative to current influenza vaccines.
• Wider adoption of LAIVs, especially in children, is recommended due to improved administration and compliance.